 | • レポートコード：QY2203B04721 • 出版社/出版日：QYResearch / 2022年3月25日 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界のバイオシミラーインスリンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にバイオシミラーインスリンの世界市場のxxx％を占める「バイオシミラーインスリングラルギン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のバイオシミラーインスリンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのバイオシミラーインスリン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのバイオシミラーインスリン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 バイオシミラーインスリンのグローバル主要メーカーには、Eli Lilly、Sanofi、Gan&Lee、Tonghua Dongbao、United Laboratory、Geropharm、Biocon、Wockhardtなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 バイオシミラーインスリン市場は、種類と用途によって区分されます。世界のバイオシミラーインスリン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 バイオシミラーインスリングラルギン、バイオシミラーインスリンリスプロ、その他 【用途別セグメント】 病院、小売薬局、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - バイオシミラーインスリン製品概要 - 種類別市場（バイオシミラーインスリングラルギン、バイオシミラーインスリンリスプロ、その他） - 用途別市場（病院、小売薬局、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のバイオシミラーインスリン販売量予測2017-2028 - 世界のバイオシミラーインスリン売上予測2017-2028 - バイオシミラーインスリンの地域別販売量 - バイオシミラーインスリンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別バイオシミラーインスリン販売量 - 主要メーカー別バイオシミラーインスリン売上 - 主要メーカー別バイオシミラーインスリン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（バイオシミラーインスリングラルギン、バイオシミラーインスリンリスプロ、その他） - バイオシミラーインスリンの種類別販売量 - バイオシミラーインスリンの種類別売上 - バイオシミラーインスリンの種類別価格 ・用途別市場規模（病院、小売薬局、その他） - バイオシミラーインスリンの用途別販売量 - バイオシミラーインスリンの用途別売上 - バイオシミラーインスリンの用途別価格 ・北米市場 - 北米のバイオシミラーインスリン市場規模（種類別、用途別） - 主要国別のバイオシミラーインスリン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのバイオシミラーインスリン市場規模（種類別、用途別） - 主要国別のバイオシミラーインスリン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のバイオシミラーインスリン市場規模（種類別、用途別） - 主要国別のバイオシミラーインスリン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のバイオシミラーインスリン市場規模（種類別、用途別） - 主要国別のバイオシミラーインスリン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのバイオシミラーインスリン市場規模（種類別、用途別） - 主要国別のバイオシミラーインスリン市場規模（トルコ、サウジアラビア） ・企業情報 Eli Lilly、Sanofi、Gan&Lee、Tonghua Dongbao、United Laboratory、Geropharm、Biocon、Wockhardt ・産業チェーン及び販売チャネル分析 - バイオシミラーインスリンの産業チェーン分析 - バイオシミラーインスリンの原材料 - バイオシミラーインスリンの生産プロセス - バイオシミラーインスリンの販売及びマーケティング - バイオシミラーインスリンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - バイオシミラーインスリンの産業動向 - バイオシミラーインスリンのマーケットドライバー - バイオシミラーインスリンの課題 - バイオシミラーインスリンの阻害要因 ・主な調査結果 |
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product’s patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Market Analysis and Insights: Global Biosimilar Insulin Market
Due to the COVID-19 pandemic, the global Biosimilar Insulin market size is estimated to be worth US$ 2952.1 million in 2022 and is forecast to a readjusted size of US$ 6548.3 million by 2028 with a CAGR of 14.2% during the review period. Fully considering the economic change by this health crisis, Biosimilar Insulin Glargine accounting for % of the Biosimilar Insulin global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
Global Biosimilar Insulin Scope and Segment
Biosimilar Insulin market is segmented by Type and by Distribution Channel. Players, stakeholders, and other participants in the global Biosimilar Insulin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Distribution Channel for the period 2017-2028.
Segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
By Company
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Biosimilar Insulin Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilar Insulin Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
1.3 Market by Distribution Channel
1.3.1 Global Biosimilar Insulin Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biosimilar Insulin Sales Estimates and Forecasts 2017-2028
2.2 Global Biosimilar Insulin Revenue Estimates and Forecasts 2017-2028
2.3 Global Biosimilar Insulin Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Biosimilar Insulin Sales by Region
2.4.1 Global Biosimilar Insulin Sales by Region (2017-2022)
2.4.2 Global Sales Biosimilar Insulin by Region (2023-2028)
2.5 Global Biosimilar Insulin Revenue by Region
2.5.1 Global Biosimilar Insulin Revenue by Region (2017-2022)
2.5.2 Global Biosimilar Insulin Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Biosimilar Insulin Sales by Manufacturers
3.1.1 Global Top Biosimilar Insulin Manufacturers by Sales (2017-2022)
3.1.2 Global Biosimilar Insulin Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilar Insulin in 2021
3.2 Global Biosimilar Insulin Revenue by Manufacturers
3.2.1 Global Biosimilar Insulin Revenue by Manufacturers (2017-2022)
3.2.2 Global Biosimilar Insulin Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Insulin Revenue in 2021
3.3 Global Biosimilar Insulin Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Biosimilar Insulin Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biosimilar Insulin Sales by Type
4.1.1 Global Biosimilar Insulin Historical Sales by Type (2017-2022)
4.1.2 Global Biosimilar Insulin Forecasted Sales by Type (2023-2028)
4.1.3 Global Biosimilar Insulin Sales Market Share by Type (2017-2028)
4.2 Global Biosimilar Insulin Revenue by Type
4.2.1 Global Biosimilar Insulin Historical Revenue by Type (2017-2022)
4.2.2 Global Biosimilar Insulin Forecasted Revenue by Type (2023-2028)
4.2.3 Global Biosimilar Insulin Revenue Market Share by Type (2017-2028)
4.3 Global Biosimilar Insulin Price by Type
4.3.1 Global Biosimilar Insulin Price by Type (2017-2022)
4.3.2 Global Biosimilar Insulin Price Forecast by Type (2023-2028)
5 Market Size by Distribution Channel
5.1 Global Biosimilar Insulin Sales by Distribution Channel
5.1.1 Global Biosimilar Insulin Historical Sales by Distribution Channel (2017-2022)
5.1.2 Global Biosimilar Insulin Forecasted Sales by Distribution Channel (2023-2028)
5.1.3 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
5.2 Global Biosimilar Insulin Revenue by Distribution Channel
5.2.1 Global Biosimilar Insulin Historical Revenue by Distribution Channel (2017-2022)
5.2.2 Global Biosimilar Insulin Forecasted Revenue by Distribution Channel (2023-2028)
5.2.3 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
5.3 Global Biosimilar Insulin Price by Distribution Channel
5.3.1 Global Biosimilar Insulin Price by Distribution Channel (2017-2022)
5.3.2 Global Biosimilar Insulin Price Forecast by Distribution Channel (2023-2028)
6 North America
6.1 North America Biosimilar Insulin Market Size by Type
6.1.1 North America Biosimilar Insulin Sales by Type (2017-2028)
6.1.2 North America Biosimilar Insulin Revenue by Type (2017-2028)
6.2 North America Biosimilar Insulin Market Size by Distribution Channel
6.2.1 North America Biosimilar Insulin Sales by Distribution Channel (2017-2028)
6.2.2 North America Biosimilar Insulin Revenue by Distribution Channel (2017-2028)
6.3 North America Biosimilar Insulin Market Size by Country
6.3.1 North America Biosimilar Insulin Sales by Country (2017-2028)
6.3.2 North America Biosimilar Insulin Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Biosimilar Insulin Market Size by Type
7.1.1 Europe Biosimilar Insulin Sales by Type (2017-2028)
7.1.2 Europe Biosimilar Insulin Revenue by Type (2017-2028)
7.2 Europe Biosimilar Insulin Market Size by Distribution Channel
7.2.1 Europe Biosimilar Insulin Sales by Distribution Channel (2017-2028)
7.2.2 Europe Biosimilar Insulin Revenue by Distribution Channel (2017-2028)
7.3 Europe Biosimilar Insulin Market Size by Country
7.3.1 Europe Biosimilar Insulin Sales by Country (2017-2028)
7.3.2 Europe Biosimilar Insulin Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biosimilar Insulin Market Size by Type
8.1.1 Asia Pacific Biosimilar Insulin Sales by Type (2017-2028)
8.1.2 Asia Pacific Biosimilar Insulin Revenue by Type (2017-2028)
8.2 Asia Pacific Biosimilar Insulin Market Size by Distribution Channel
8.2.1 Asia Pacific Biosimilar Insulin Sales by Distribution Channel (2017-2028)
8.2.2 Asia Pacific Biosimilar Insulin Revenue by Distribution Channel (2017-2028)
8.3 Asia Pacific Biosimilar Insulin Market Size by Region
8.3.1 Asia Pacific Biosimilar Insulin Sales by Region (2017-2028)
8.3.2 Asia Pacific Biosimilar Insulin Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Biosimilar Insulin Market Size by Type
9.1.1 Latin America Biosimilar Insulin Sales by Type (2017-2028)
9.1.2 Latin America Biosimilar Insulin Revenue by Type (2017-2028)
9.2 Latin America Biosimilar Insulin Market Size by Distribution Channel
9.2.1 Latin America Biosimilar Insulin Sales by Distribution Channel (2017-2028)
9.2.2 Latin America Biosimilar Insulin Revenue by Distribution Channel (2017-2028)
9.3 Latin America Biosimilar Insulin Market Size by Country
9.3.1 Latin America Biosimilar Insulin Sales by Country (2017-2028)
9.3.2 Latin America Biosimilar Insulin Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Biosimilar Insulin Market Size by Type
10.1.1 Middle East and Africa Biosimilar Insulin Sales by Type (2017-2028)
10.1.2 Middle East and Africa Biosimilar Insulin Revenue by Type (2017-2028)
10.2 Middle East and Africa Biosimilar Insulin Market Size by Distribution Channel
10.2.1 Middle East and Africa Biosimilar Insulin Sales by Distribution Channel (2017-2028)
10.2.2 Middle East and Africa Biosimilar Insulin Revenue by Distribution Channel (2017-2028)
10.3 Middle East and Africa Biosimilar Insulin Market Size by Country
10.3.1 Middle East and Africa Biosimilar Insulin Sales by Country (2017-2028)
10.3.2 Middle East and Africa Biosimilar Insulin Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Eli Lilly Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eli Lilly Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Sanofi Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi Recent Developments
11.3 Gan&Lee
11.3.1 Gan&Lee Corporation Information
11.3.2 Gan&Lee Overview
11.3.3 Gan&Lee Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Gan&Lee Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Gan&Lee Recent Developments
11.4 Tonghua Dongbao
11.4.1 Tonghua Dongbao Corporation Information
11.4.2 Tonghua Dongbao Overview
11.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Tonghua Dongbao Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Tonghua Dongbao Recent Developments
11.5 United Laboratory
11.5.1 United Laboratory Corporation Information
11.5.2 United Laboratory Overview
11.5.3 United Laboratory Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 United Laboratory Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 United Laboratory Recent Developments
11.6 Geropharm
11.6.1 Geropharm Corporation Information
11.6.2 Geropharm Overview
11.6.3 Geropharm Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Geropharm Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Geropharm Recent Developments
11.7 Biocon
11.7.1 Biocon Corporation Information
11.7.2 Biocon Overview
11.7.3 Biocon Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Biocon Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Biocon Recent Developments
11.8 Wockhardt
11.8.1 Wockhardt Corporation Information
11.8.2 Wockhardt Overview
11.8.3 Wockhardt Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Wockhardt Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Wockhardt Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biosimilar Insulin Industry Chain Analysis
12.2 Biosimilar Insulin Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilar Insulin Production Mode & Process
12.4 Biosimilar Insulin Sales and Marketing
12.4.1 Biosimilar Insulin Sales Channels
12.4.2 Biosimilar Insulin Distributors
12.5 Biosimilar Insulin Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Biosimilar Insulin Industry Trends
13.2 Biosimilar Insulin Market Drivers
13.3 Biosimilar Insulin Market Challenges
13.4 Biosimilar Insulin Market Restraints
14 Key Findings in The Global Biosimilar Insulin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Biosimilar Insulin Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Biosimilar Insulin Glargine
Table 3. Major Manufacturers of Biosimilar Insulin Lispro
Table 4. Major Manufacturers of Other
Table 5. Global Biosimilar Insulin Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Biosimilar Insulin Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Biosimilar Insulin Sales by Region (2017-2022) & (K Unit)
Table 8. Global Biosimilar Insulin Sales Market Share by Region (2017-2022)
Table 9. Global Biosimilar Insulin Sales by Region (2023-2028) & (K Unit)
Table 10. Global Biosimilar Insulin Sales Market Share by Region (2023-2028)
Table 11. Global Biosimilar Insulin Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Biosimilar Insulin Revenue Market Share by Region (2017-2022)
Table 13. Global Biosimilar Insulin Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Biosimilar Insulin Revenue Market Share by Region (2023-2028)
Table 15. Global Biosimilar Insulin Sales by Manufacturers (2017-2022) & (K Unit)
Table 16. Global Biosimilar Insulin Sales Share by Manufacturers (2017-2022)
Table 17. Global Biosimilar Insulin Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Biosimilar Insulin Revenue Share by Manufacturers (2017-2022)
Table 19. Biosimilar Insulin Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Biosimilar Insulin Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Biosimilar Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin as of 2021)
Table 22. Biosimilar Insulin Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Biosimilar Insulin Product Offered
Table 24. Date of Manufacturers Enter into Biosimilar Insulin Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 27. Global Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 28. Global Biosimilar Insulin Sales Share by Type (2017-2022)
Table 29. Global Biosimilar Insulin Sales Share by Type (2023-2028)
Table 30. Global Biosimilar Insulin Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Biosimilar Insulin Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Biosimilar Insulin Revenue Share by Type (2017-2022)
Table 33. Global Biosimilar Insulin Revenue Share by Type (2023-2028)
Table 34. Biosimilar Insulin Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Biosimilar Insulin Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 37. Global Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 38. Global Biosimilar Insulin Sales Share by Distribution Channel (2017-2022)
Table 39. Global Biosimilar Insulin Sales Share by Distribution Channel (2023-2028)
Table 40. Global Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 41. Global Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 42. Global Biosimilar Insulin Revenue Share by Distribution Channel (2017-2022)
Table 43. Global Biosimilar Insulin Revenue Share by Distribution Channel (2023-2028)
Table 44. Biosimilar Insulin Price by Distribution Channel (2017-2022) & (US$/Unit)
Table 45. Global Biosimilar Insulin Price Forecast by Distribution Channel (2023-2028) & (US$/Unit)
Table 46. North America Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 47. North America Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 48. North America Biosimilar Insulin Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Biosimilar Insulin Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 51. North America Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 52. North America Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 53. North America Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 54. North America Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 55. North America Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 56. North America Biosimilar Insulin Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Biosimilar Insulin Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 59. Europe Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 60. Europe Biosimilar Insulin Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Biosimilar Insulin Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 63. Europe Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 64. Europe Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 65. Europe Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 66. Europe Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 67. Europe Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 68. Europe Biosimilar Insulin Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Biosimilar Insulin Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 71. Asia Pacific Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 72. Asia Pacific Biosimilar Insulin Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Biosimilar Insulin Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 75. Asia Pacific Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 76. Asia Pacific Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 77. Asia Pacific Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 78. Asia Pacific Biosimilar Insulin Sales by Region (2017-2022) & (K Unit)
Table 79. Asia Pacific Biosimilar Insulin Sales by Region (2023-2028) & (K Unit)
Table 80. Asia Pacific Biosimilar Insulin Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Biosimilar Insulin Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 83. Latin America Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 84. Latin America Biosimilar Insulin Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Biosimilar Insulin Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 87. Latin America Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 88. Latin America Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 89. Latin America Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 90. Latin America Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 91. Latin America Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 92. Latin America Biosimilar Insulin Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Biosimilar Insulin Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Biosimilar Insulin Sales by Type (2017-2022) & (K Unit)
Table 95. Middle East and Africa Biosimilar Insulin Sales by Type (2023-2028) & (K Unit)
Table 96. Middle East and Africa Biosimilar Insulin Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Biosimilar Insulin Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Biosimilar Insulin Sales by Distribution Channel (2017-2022) & (K Unit)
Table 99. Middle East and Africa Biosimilar Insulin Sales by Distribution Channel (2023-2028) & (K Unit)
Table 100. Middle East and Africa Biosimilar Insulin Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Biosimilar Insulin Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Biosimilar Insulin Sales by Country (2017-2022) & (K Unit)
Table 103. Middle East and Africa Biosimilar Insulin Sales by Country (2023-2028) & (K Unit)
Table 104. Middle East and Africa Biosimilar Insulin Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Biosimilar Insulin Revenue by Country (2023-2028) & (US$ Million)
Table 106. Eli Lilly Corporation Information
Table 107. Eli Lilly Description and Major Businesses
Table 108. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Eli Lilly Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Eli Lilly Recent Developments
Table 111. Sanofi Corporation Information
Table 112. Sanofi Description and Major Businesses
Table 113. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Sanofi Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Sanofi Recent Developments
Table 116. Gan&Lee Corporation Information
Table 117. Gan&Lee Description and Major Businesses
Table 118. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Gan&Lee Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Gan&Lee Recent Developments
Table 121. Tonghua Dongbao Corporation Information
Table 122. Tonghua Dongbao Description and Major Businesses
Table 123. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Tonghua Dongbao Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Tonghua Dongbao Recent Developments
Table 126. United Laboratory Corporation Information
Table 127. United Laboratory Description and Major Businesses
Table 128. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. United Laboratory Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. United Laboratory Recent Developments
Table 131. Geropharm Corporation Information
Table 132. Geropharm Description and Major Businesses
Table 133. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Geropharm Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Geropharm Recent Developments
Table 136. Biocon Corporation Information
Table 137. Biocon Description and Major Businesses
Table 138. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Biocon Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Biocon Recent Developments
Table 141. Wockhardt Corporation Information
Table 142. Wockhardt Description and Major Businesses
Table 143. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. Wockhardt Biosimilar Insulin Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Wockhardt Recent Developments
Table 146. Key Raw Materials Lists
Table 147. Raw Materials Key Suppliers Lists
Table 148. Biosimilar Insulin Distributors List
Table 149. Biosimilar Insulin Customers List
Table 150. Biosimilar Insulin Market Trends
Table 151. Biosimilar Insulin Market Drivers
Table 152. Biosimilar Insulin Market Challenges
Table 153. Biosimilar Insulin Market Restraints
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Insulin Product Picture
Figure 3. Global Biosimilar Insulin Market Share by Type in 2021 & 2028
Figure 3. Biosimilar Insulin Glargine Product Picture
Figure 4. Biosimilar Insulin Lispro Product Picture
Figure 5. Other Product Picture
Figure 6. Global Biosimilar Insulin Market Share by Distribution Channel in 2021 & 2028
Figure 7. Hospital
Figure 8. Retail Pharmacy
Figure 9. Others
Figure 10. Biosimilar Insulin Report Years Considered
Figure 11. Global Biosimilar Insulin Sales 2017-2028 (K Unit)
Figure 12. Global Biosimilar Insulin Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Biosimilar Insulin Revenue 2017-2028 (US$ Million)
Figure 14. Global Biosimilar Insulin Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Biosimilar Insulin Sales Market Share by Region (2017-2022)
Figure 16. Global Biosimilar Insulin Sales Market Share by Region (2023-2028)
Figure 17. North America Biosimilar Insulin Sales YoY (2017-2028) & (K Unit)
Figure 18. North America Biosimilar Insulin Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Biosimilar Insulin Sales YoY (2017-2028) & (K Unit)
Figure 20. Europe Biosimilar Insulin Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Biosimilar Insulin Sales YoY (2017-2028) & (K Unit)
Figure 22. Asia-Pacific Biosimilar Insulin Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Biosimilar Insulin Sales YoY (2017-2028) & (K Unit)
Figure 24. Latin America Biosimilar Insulin Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Biosimilar Insulin Sales YoY (2017-2028) & (K Unit)
Figure 26. Middle East & Africa Biosimilar Insulin Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Biosimilar Insulin Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Biosimilar Insulin in the World: Market Share by Biosimilar Insulin Revenue in 2021
Figure 29. Global Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 31. Global Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 32. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 33. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 34. North America Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 35. North America Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 36. North America Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 37. North America Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 38. North America Biosimilar Insulin Sales Share by Country (2017-2028)
Figure 39. North America Biosimilar Insulin Revenue Share by Country (2017-2028)
Figure 40. United States Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 43. Europe Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 44. Europe Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 45. Europe Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 46. Europe Biosimilar Insulin Sales Share by Country (2017-2028)
Figure 47. Europe Biosimilar Insulin Revenue Share by Country (2017-2028)
Figure 48. Germany Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 49. France Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 56. Asia Pacific Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 57. Asia Pacific Biosimilar Insulin Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Biosimilar Insulin Revenue Share by Region (2017-2028)
Figure 59. China Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 62. India Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 69. Latin America Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 71. Latin America Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 72. Latin America Biosimilar Insulin Sales Share by Country (2017-2028)
Figure 73. Latin America Biosimilar Insulin Revenue Share by Country (2017-2028)
Figure 74. Mexico Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Biosimilar Insulin Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Biosimilar Insulin Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2028)
Figure 80. Middle East and Africa Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2028)
Figure 81. Middle East and Africa Biosimilar Insulin Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Biosimilar Insulin Revenue Share by Country (2017-2028)
Figure 83. Turkey Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Biosimilar Insulin Revenue (2017-2028) & (US$ Million)
Figure 86. Biosimilar Insulin Value Chain
Figure 87. Biosimilar Insulin Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed